ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BioCryst announces $325m of funding from Royalty Pharma and Athyrium Capital Management
December 11, 2020BioCryst Pharmaceuticals, Royalty Pharma, and Athyrium Capital Management, announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO (berotralstat) in hereditary ... -
BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930
March 10, 2020BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH).
Pharma Sources Insight January 2025
